Pages

Thursday, April 19, 2012

J&J's penalty is $1.1 billion in Risperdal case

11:59 AM, Apr. 11, 2012
Johnson & Johnson was told to pay $1.1 billion by a state judge after an Arkansas jury found the company’s officials misled doctors and patients about the risks of the antipsychotic drug Risperdal.
Jurors in Little Rock yesterday said the company’s marketing campaign also violated consumer-protection laws. The panel deliberated about three hours before finding J&J and its Janssen unit engaged in "false or deceptive acts" by sending a 2003 letter touting Risperdal as safer than competing drugs to more than 6,000 doctors across the state.

The state was seeking more than $1.25 billion in penalties over the Risperdal marketing campaign. It’s the third jury verdict against J&J, the second-biggest maker of health products, in cases where states alleged it hid Risperdal’s risks and tricked Medicaid regulators into paying more than they should have for the medicine. Louisiana and South Carolina juries also found the company’s Risperdal marketing violated consumer-protection laws.  READ MORE
 

1 comment:

Daniel Haszard said...

A customer victim speaks
Risperdal reproached.
The saga of the so called *atypical antipsychotics* is one of incredible profit.Eli Lilly made $65 BILLION on Zyprexa.Described as *the most successful drug in the history of neuroscience* the drugs at $12 pill are used by states to medicate deinstitutionalized mental patients to keep them out of the $500 day hospitals.
There is a whole underclass block of our society,including children in foster care that are the market for these drugs,but have little voice of protest if harmed by them.I am an exception,I got diabetes from Zyprexa as an off-label treatment for PTSD and I am not a mentally challenged victim so I post.
--Daniel Haszard FMI zyprexa-victims(dot)com